Holy Stone Healthcare
Taipei, Taiwan· Est.
Taiwan biotech leveraging hyaluronic‑acid biopolymers for targeted brain, eye, and tumor drug delivery.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Taiwan biotech leveraging hyaluronic‑acid biopolymers for targeted brain, eye, and tumor drug delivery.
OncologyOphthalmologyNeurology
Technology Platform
The HylX platform uses hyaluronic‑acid‑based biopolymers for targeted, controlled delivery of therapeutics across the blood‑brain barrier, ocular barriers, and tumor microenvironments.
Opportunities
Strategic licensing with pharma for HA‑based delivery and expansion into high‑growth neurology and ophthalmology markets.
Risk Factors
Technical risk of achieving regulatory approval for novel polymer carriers and reliance on external funding for clinical progression.
Competitive Landscape
Few companies specialize in HA‑based delivery; HSHC differentiates through its modular HylX platform and strong IP portfolio.